TrialNature medicine2023

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.

Matthew D Galsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.